KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Short term Debt (2023 - 2025)

Rigel Pharmaceuticals (RIGL) has 3 years of Short term Debt data on record, last reported at $29.8 million in Q4 2025.

  • For Q4 2025, Short term Debt rose 309.96% year-over-year to $29.8 million; the TTM value through Dec 2025 reached $29.8 million, up 309.96%, while the annual FY2025 figure was $29.8 million, 309.96% up from the prior year.
  • Short term Debt reached $29.8 million in Q4 2025 per RIGL's latest filing, roughly flat from $29.8 million in the prior quarter.
  • Across five years, Short term Debt topped out at $29.8 million in Q4 2025 and bottomed at $7.2 million in Q4 2023.
  • Average Short term Debt over 3 years is $18.0 million, with a median of $14.8 million recorded in 2025.
  • The widest YoY moves for Short term Debt: up 309.96% in 2025, down 0.24% in 2025.
  • A 3-year view of Short term Debt shows it stood at $7.2 million in 2023, then rose by 0.59% to $7.3 million in 2024, then skyrocketed by 309.96% to $29.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $29.8 million in Q4 2025, $29.8 million in Q3 2025, and $22.4 million in Q2 2025.